Animal Models for Medical Countermeasures to Radiation Exposure

TLDR

Since 9/11, the threat of radiological terrorism has prompted the U.S. to establish a network of Centers for Medical Countermeasures against Radiation to develop agents for civilian use. To meet FDA’s Animal Rule, CMCR investigators convened an Animal Models Workshop in 2008 to reach consensus on species, strains, and factors for evaluating agent efficacy across immune, hematopoietic, gastrointestinal, pulmonary, renal, and cutaneous tissues.

Abstract

Since September 11, 2001, there has been the recognition of a plausible threat from acts of terrorism, including radiological or nuclear attacks. A network of Centers for Medical Countermeasures against Radiation (CMCRs) has been established across the U.S.; one of the missions of this network is to identify and develop mitigating agents that can be used to treat the civilian population after a radiological event. The development of such agents requires comparison of data from many sources and accumulation of information consistent with the “Animal Rule” from the Food and Drug Administration (FDA). Given the necessity for a consensus on appropriate animal model use across the network to allow for comparative studies to be performed across institutions, and to identify pivotal studies and facilitate FDA approval, in early 2008, investigators from each of the CMCRs organized and met for an Animal Models Workshop. Working groups deliberated and discussed the wide range of animal models available for assessing agent efficacy in a number of relevant tissues and organs, including the immune and hematopoietic systems, gastrointestinal tract, lung, kidney and skin. Discussions covered the most appropriate species and strains available as well as other factors that may affect differential findings between groups and institutions. This report provides the workshop findings.